New York State Teachers Retirement System Sells 9,111 Shares of Hologic, Inc. (NASDAQ:HOLX)

Posted by on Apr 12th, 2023

New York State Teachers Retirement System lessened its holdings in Hologic, Inc. (NASDAQ:HOLX – Get Rating) by 2.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 330,384 shares of the medical equipment provider’s stock after selling 9,111 shares during the quarter. New York State Teachers Retirement System owned 0.13% of Hologic worth $24,716,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of HOLX. Vanguard Group Inc. grew its holdings in shares of Hologic by 0.3% in the third quarter. Vanguard Group Inc. now owns 28,420,602 shares of the medical equipment provider’s stock valued at $1,833,698,000 after acquiring an additional 97,603 shares in the last quarter. BlackRock Inc. lifted its holdings in Hologic by 1.5% in the third quarter. BlackRock Inc. now owns 23,397,083 shares of the medical equipment provider’s stock worth $1,509,579,000 after buying an additional 345,453 shares during the period. State Street Corp lifted its holdings in shares of Hologic by 0.6% during the third quarter. State Street Corp now owns 11,550,359 shares of the medical equipment provider’s stock valued at $745,229,000 after purchasing an additional 73,451 shares during the last quarter. Macquarie Group Ltd. increased its position in shares of Hologic by 227.2% during the second quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock valued at $435,485,000 after acquiring an additional 4,363,687 shares in the last quarter. Finally, Victory Capital Management Inc. grew its position in Hologic by 18.7% in the 3rd quarter. Victory Capital Management Inc. now owns 4,266,481 shares of the medical equipment provider’s stock worth $275,273,000 after purchasing an additional 672,414 shares during the period. 95.17% of the stock is currently owned by institutional investors.

Insider Transactions at Hologic

In other news, insider Benjamin Jordan Cohn sold 9,128 shares of the company’s stock in a transaction on Tuesday, February 7th. The stock was sold at an average price of $85.28, for a total transaction of $778,435.84. Following the completion of the sale, the insider now directly owns 14,298 shares in the company, valued at approximately $1,219,333.44. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.66% of the stock is currently owned by corporate insiders.

Hologic Price Performance

Shares of HOLX opened at $83.54 on Wednesday. Hologic, Inc. has a 1 year low of $59.78 and a 1 year high of $86.65. The company has a current ratio of 4.21, a quick ratio of 3.50 and a debt-to-equity ratio of 0.55. The stock has a market cap of $20.60 billion, a P/E ratio of 21.31, a price-to-earnings-growth ratio of 1.46 and a beta of 1.00. The stock’s 50-day moving average price is $80.96 and its two-hundred day moving average price is $75.79.

Hologic (NASDAQ:HOLX – Get Rating) last announced its earnings results on Wednesday, February 1st. The medical equipment provider reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.17. The business had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 25.12% and a net margin of 22.17%. Hologic’s revenue for the quarter was down 27.0% compared to the same quarter last year. During the same quarter last year, the firm earned $2.17 EPS. On average, equities analysts predict that Hologic, Inc. will post 3.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HOLX has been the topic of several research analyst reports. Wells Fargo & Company boosted their price target on shares of Hologic from $75.00 to $80.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 10th. StockNews.com downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Wednesday, April 5th. SVB Leerink lifted their price target on shares of Hologic from $90.00 to $93.00 and gave the company an “outperform” rating in a research report on Thursday, February 2nd. Cowen boosted their price target on shares of Hologic from $86.00 to $95.00 and gave the stock an “outperform” rating in a report on Thursday, February 2nd. Finally, JPMorgan Chase & Co. increased their price target on shares of Hologic from $90.00 to $95.00 and gave the stock an “overweight” rating in a research note on Thursday, February 2nd. Nine research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, Hologic currently has a consensus rating of “Hold” and an average target price of $84.08.

Hologic Profile

(Get Rating)

Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.

Featured Articles

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Get Rating).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.